We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

117 hedge funds and large institutions have $164M invested in Rigel Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,976% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $50K

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

4% more funds holding

Funds holding: 112 → 117 (+5)

0.61% less ownership

Funds ownership: 6.94% → 6.33% (-0.61%)

8% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 38

7% less capital invested

Capital invested by funds: $176M → $164M (-$11.8M)

Holders
117
Holders Change
+5
Holders Change %
+4.46%
% of All Funds
1.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
35
Reduced
38
Closed
12
Calls
$1.04M
Puts
$50K
Net Calls
+$988K
Net Calls Change
-$324K

Top Buyers

1
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$1.83M
2
Millennium Management
Millennium Management
New York
+$1.48M
3
SCM
Stonepine Capital Management
Oregon
+$1.4M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.14M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.12M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$19.5M
2
AC
Armistice Capital
New York
-$2.34M
3
SFM
Sphera Funds Management
Israel
-$1.78M
4
BlackRock
BlackRock
New York
-$538K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$532K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$22.7M -$2.34M -174,000 -10%
BlackRock
2
BlackRock
New York
$21.9M -$538K -39,934 -3%
Morgan Stanley
3
Morgan Stanley
New York
$21.4M -$19.5M -1,446,937 -50%
Vanguard Group
4
Vanguard Group
Pennsylvania
$13.9M +$558K +41,420 +5%
SCM
5
Soleus Capital Management
Connecticut
$13.7M -$270K -20,059 -2%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$8.09M +$1.14M +84,342 +18%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$5.61M +$135K +9,980 +3%
State Street
8
State Street
Massachusetts
$5.53M +$209K +15,472 +4%
N
9
Nuveen
North Carolina
$4.77M +$1.02M +75,668 +31%
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$3.39M -$532K -39,463 -15%
Renaissance Technologies
11
Renaissance Technologies
New York
$2.99M +$946K +70,196 +53%
CM
12
CM Management
Florida
$2.96M +$404K +30,000 +18%
Assenagon Asset Management
13
Assenagon Asset Management
Luxembourg
$2.95M – – –
Millennium Management
14
Millennium Management
New York
$2.77M +$1.48M +109,715 +141%
VOYA Investment Management
15
VOYA Investment Management
Georgia
$2.68M -$376K -27,915 -13%
Macquarie Group
16
Macquarie Group
Australia
$2.37M – – –
Northern Trust
17
Northern Trust
Illinois
$2.14M -$126K -9,385 -6%
GCP
18
GSA Capital Partners
United Kingdom
$2.04M -$64K -4,751 -3%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
19
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$2.01M +$1.83M +135,920 New
SCM
20
Stonepine Capital Management
Oregon
$1.54M +$1.4M +104,024 New
Wellington Management Group
21
Wellington Management Group
Massachusetts
$1.23M +$1.12M +83,416 New
Charles Schwab
22
Charles Schwab
California
$1.1M – – –
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.08M +$193K +14,355 +24%
UOC
24
UBS O'Connor
Illinois
$996K -$305K -22,659 -25%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$922K -$47.7K -3,541 -5%
1
2 3 4 5

RIGL Hedge Fund Activity: Q1 2024 in Review

117 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2024, worth a combined $164M — down 6.7% from $176M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 38 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $1.83M. The largest seller was Morgan Stanley, cutting an estimated $19.5M.

  • 117 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2024, up from 112 in Q4 2023.
  • Funds reported $164M of Rigel Pharmaceuticals stock for Q1 2024, down 6.7% quarter-over-quarter.
  • 17 funds opened new Rigel Pharmaceuticals positions in Q1 2024 and 12 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.83M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2024.